Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled Study of MD-120 (desvenlafaxine) in Major Depressive Disorder
jRCT2080225156Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Started Apr 2020; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080225156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225156.